At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 278 enrolled
Drug / intervention
LY3209590 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating LY3209590 and Insulin Degludec for Type 2 Diabetes Mellitus. Completed, enrolled 278 participants across 64 sites in 5 countries.
Detailed Summary
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesArgentina, Germany, Poland, Puerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionOct 2021
TodayJul 2026
First PostedJun 29, 2020
Enrollment StartJul 1, 2020
Primary CompletionOct 8, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.0 years ago
Interventions
LY3209590drug
Administered SC
Insulin Degludecdrug
Administered SC